HOME >> MEDICINE >> NEWS
Medication may promote opening of arteries following stroke

A medication known as argatroban, when combined with another drug already used in the treatment of stroke patients, may help restore the flow of blood through blocked arteries, according to a preliminary study in the August issue of Archives of Neurology, one of the JAMA/Archives journals.

Ischemic stroke, the most common type of stroke, generally occurs when a blood clot lodges in an artery, blocking blood flow to the brain. Some patients with ischemic stroke are treated quickly with intravenous recombinant tissue plasminogen activator (rtPA), which works to help dissolve the clot and reopen the artery. However, some patients do not respond to rtPA alone, according to background information in the article. In animals, argatroban--which blocks the action of chemicals that clot the blood--has been shown to work with rtPA, increasing blood flow, speeding the opening of blood vessels and preventing recurring blockages. Argatroban is approved for use in patients with heart attacks to help prevent clots but has not been tested in human stroke victims.

Rebecca M. Sugg, M.D., University of TexasHouston Medical School, and colleagues evaluated the safety and efficacy of the drug combination in 15 stroke patients (10 men and five women, average age 61 years) who had blockages in the cerebral arteries, major blood vessels leading to the brain. Patients received the standard dose of rtPA intravenously an average of 118 minutes after their symptoms began, with the initial dose of the drug administered in one minute and the rest infused over the period of an hour. Within one hour of rtPA treatment (an average of 172 minutes after symptoms began), the patients received a large dose of argatroban followed by a continuous 48-hour infusion. Patients were watched closely for signs of excessive bleeding (hemorrhage), the most common risk associated with drugs that prevent clotting; all but one participant, who showed initial signs of hemorrhage, received
'"/>

Contact: Deborah Mann Lake
713-500-3030
JAMA and Archives Journals
14-Aug-2006


Page: 1 2

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Medication errors affect childrens leukemia treatment
3. IOM Advisory: Preventing Medication Errors News Conference on July 20
4. Medication use linked to farmers injuries
5. Medication plus oral contraceptive may improve female pattern hair loss
6. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
7. Medications that lower blood pressure linked to reduced risk of Alzheimers disease
8. Medication shows modest benefit in reducing weight, improving HDL, triglyceride levels
9. Medication plus beta-blocker helps prevent shocks from implantable cardioverter defibrillator
10. Medications and cough syrups may cause cavities
11. Medication reduces risk of heart irregularities after cardiac surgery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Medication may promote opening arteries following stroke

(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 An article ... problem which could prove critical to organizations that deal ... a critical aspect of data security, is worsening . ... data security report, every major category out of the ... penetration testing. “With all the craziness that has gone ...
(Date:3/28/2015)... 28, 2015 Delaying rotator cuff surgery ... according to research presented today at the American Orthopaedic ... , “Our study compared results for 170 patients who ... additional glenohumeral joint capsule release procedure to relieve stiffness ... PhD, lead author from St. George Hospital in Sydney, ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
Breaking Medicine News(10 mins):Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2
(Date:3/27/2015)... , March 27, 2015   Hospira, Inc. ... in biosimilars and the world,s leading provider of ... that support an evaluation of biosimilarity of its ... and Drug Administration (FDA) conditionally approved name of ... (epoetin alfa). These study data were presented at ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
Cached News: